Documentary highlights new targets to potentially treat motor neurone disease
Pharma Times
NOVEMBER 14, 2023
The terminal condition currently affects around 5,000 people in the UK - News - PharmaTimes
Tue.Nov 14, 2023
145 
Forbion-backed biotech raises $138M to develop ALS drug
Bio Pharma Dive
NOVEMBER 14, 2023
The Series A round for three-year-old startup VectorY is one of the largest private financings in Europe this year, Forbion said.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Four-Week Experiment Reveals an Ingeniously Simple Way to Boost Your Sleep Quality
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 14, 2023
So much of our health is tied to banking good quality sleep every night, and a new four-week experiment has revealed a simple way anyone can improve the quality of their slumber: keeping the bedroom well-ventilated.
New AMA policies target GLP-1 coverage, corporate medicine
Bio Pharma Dive
NOVEMBER 14, 2023
The lobbying group urged broader health insurance coverage for treating obesity, including with GLP-1 agonists like Wegovy.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Indian healthcare looks at pharmacogenomics in patient care as comprehensive genetic tests gain ground
AuroBlog - Aurous Healthcare Clinical Trials blog
NOVEMBER 14, 2023
Indian healthcare looks at pharmacogenomics, the study of influence of genetic factors on drug response, in patient care as comprehensive genetic tests gain ground. Global healthcare sector has witnessed a paradigm shift with the emergence of pharmacogenomics (PGx) as a game changing trend.
FDA oversees rise in awarded orphan drug designations for myelofibrosis
Pharmaceutical Technology
NOVEMBER 14, 2023
Concerns have been raised over the suitability of current FDA-approved treatments for myelofibrosis, due to the negative associations with anaemia.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Telix plans $125m acquisition of radiopharmaceuticals company QSAM
Pharmaceutical Technology
NOVEMBER 14, 2023
Telix with pay $2m upfront, with $33m on closing and up to $90m in milestone-based payments.
BBSRC to invest £12m into 62 UK bioscience research projects
Pharma Times
NOVEMBER 14, 2023
The projects will explore early-stage ideas at the frontiers of bioscience - News - PharmaTimes
Novartis signs agreement for Legend Biotech’s CAR-T therapies
Pharmaceutical Technology
NOVEMBER 14, 2023
Novartis Pharma has signed an exclusive worldwide licence agreement for Legend Biotech Ireland’s DLL3-targeting CAR-T cell therapies.
Resilience, empathy, and gratitude. A personal battle with breast cancer.
pharmaphorum
NOVEMBER 14, 2023
Resilience, empathy, and gratitude. A personal battle with breast cancer. Mike.
ProKidney amends Phase III protocol in light of Phase II results
Pharmaceutical Technology
NOVEMBER 14, 2023
React show most benefit in moderate to high-risk diabetic CKD patients, for Phase III ProKidney plans to focus on this patient population.
A researcher's perspective: Linking scientific discovery to clinical medicine
Antidote
NOVEMBER 14, 2023
For Carla Greenbaum, M.D., growing up in the era of space travel and the moon landing kindled a lifelong interest in science. That interest influenced her career trajectory, and she’s now a leading investigator at Benaroya Research Institute where she has studied the natural history of type 1 diabetes (T1D) since 2000. Her work focuses on finding the cause of autoimmunity and developing targets for treatment, which she finds “incredibly exciting and inspiring—like landing on the moon!
MBrace secures $85m to develop ADCs for oncology targets
Pharmaceutical Technology
NOVEMBER 14, 2023
MBrace Therapeutics has secured $85m in a Series B funding round to advance clinical development of ADCs for oncology targets.
AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial
pharmaphorum
NOVEMBER 14, 2023
AZ’s oncology hopes dented as Imfinzi flunks NSCLC trial Phil.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Orphelia pushes boundaries with regulatory barriers for pediatric indications
Pharmaceutical Technology
NOVEMBER 14, 2023
Orphelia has lined its discovery pipeline with a number of pediatric CNS and rare cancer indications.
J&J and Bayer's Xarelto proves its worth across PAD subgroups in 2 new analyses
Fierce Pharma
NOVEMBER 14, 2023
Johnson & Johnson and Bayer’s wide-spanning VOYAGER PAD study continues to be a gold mine for proving its Xarelto’s worth in several subsets of patients with peripheral artery disease (PAD).
AstraZeneca announces GLP-1 combo to treat obesity and co-morbidities
Pharmaceutical Technology
NOVEMBER 14, 2023
AstraZeneca has announced its strategy for the cardiometabolic market, in particular for treating obesity and its co-morbidities
AHA: First data backs AskBio’s heart failure gene therapy
pharmaphorum
NOVEMBER 14, 2023
AHA: First data backs AskBio’s heart failure gene therapy Phil.
Nouscom raises $72m in Series C financing round to develop cancer vaccines
Pharmaceutical Technology
NOVEMBER 14, 2023
The company intends to use the funds to advance its cancer vaccine clinical pipeline, including a colorectal cancer vaccine.
Autifony swings $770.5m deal with Jazz for CNS drugs
pharmaphorum
NOVEMBER 14, 2023
Autifony swings $770.5m deal with Jazz for CNS drugs Phil.
Teva and Royalty Pharma to expedite olanzapine LAI research programme
Pharmaceutical Technology
NOVEMBER 14, 2023
Teva Pharmaceuticals and Royalty Pharma have partnered on a clinical research programme for olanzapine LAI (TEV-‘749), for schizophrenia.
Best Food Inventions of 2023, According to TIME Magazine
XTalks
NOVEMBER 14, 2023
Last month, TIME Magazine unveiled its “ Best Inventions of 2023 ” list, which included 13 food inventions (up from nine last year). The magazine spotlighted 200 groundbreaking inventions that promise to transform our daily interactions, work methodologies and overall future outlook. To select the winners, TIME gathered nominations from its global network of editors and correspondents, complemented by an online application process for submissions.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Reform in South Korea means progression in improving time to reimbursement
Pharmaceutical Technology
NOVEMBER 14, 2023
South Korea has been busy with reforms that aim to expedite the introduction of new innovative drugs into its national insurance system.
Wegovy Obesity Drug Could Offer Heart Benefits According to Latest Trial Data
XTalks
NOVEMBER 14, 2023
Novo Nordisk shared new clinical trial data that shows its obesity drug Wegovy (semaglutide) can also reduce the risk of various heart complications, including heart attack, in certain individuals. Novo presented the results of the study at the American Heart Association (AHA) Scientific Sessions this past weekend in Philadelphia, which were also published in the New England Journal of Medicine.
VectorY secures $138m to develop neurodegenerative disease therapies
Pharmaceutical Technology
NOVEMBER 14, 2023
VectorY Therapeutics secured $138m in a Series A funding round to progress its vectorised antibody programmes in neurodegenerative diseases.
Pharma’s engagement with HCPs evolving, finds new poll
pharmaphorum
NOVEMBER 14, 2023
Pharma’s engagement with HCPs evolving, finds new poll Phil.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Health Canada approves Ipsen-Medison’s Bylvay for PFIC-linked pruritus
Pharmaceutical Technology
NOVEMBER 14, 2023
Health Canada has approved Ipsen-Medison Pharma’s Bylvay to treat pruritus associated with progressive familial intrahepatic cholestasis.
Merck KGaA's pharma unit joins the healthcare migration to Boston's Seaport innovation hub
Fierce Pharma
NOVEMBER 14, 2023
In little more than a decade, Boston’s transformed Seaport district—once littered with industrial buildings, warehouses and parking lots—has become an innovation hub and home to more than 25 health | Add another to the list of healthcare companies joining Boston's transformed Seaport district, as Merck KGaA's pharma subsidiary, EMD Serono, said it will move its U.S. headquarters from 25 miles south in Rockland to Seaport.
Sustainability in biopharma: The challenges of ESG 2.0
Pharmaceutical Technology
NOVEMBER 14, 2023
With demand for drug products high, biopharma will need bold strategies to address sustainability challenges of the future.
Alkermes Spins Off Oncology Business with $275M to Focus on Neuroscience
BioSpace
NOVEMBER 14, 2023
The new company, Mural Oncology, will continue registrational studies of its IL-2 cytokine in melanoma and ovarian cancer utilizing a $275 million cash runway expected to take them to the end of 2025.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content